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Context. Physicians overestimate survival in patients with advanced cancer. Patient-reported outcomes could provide
another way to estimate survival. We previously reported four prognostic groups based on Karnofsky Performance Status,
Functional Assessment of Cancer Therapy physical well-being subscale, and Memorial Symptom Assessment Scale-Short Form
physical symptom distress subscale scores.
Objectives. To determine the validity of these four prognostic groups.
Methods. We performed prospective surveys. Data from a total of 880 Veterans Affairs Medical Center patients, 417 in the
First Cohort and 463 in the Validation Cohort, were analyzed. Both inpatients and outpatients were prospectively recruited in
Institutional Review Board-approved studies from August 1999 to September 2009. Survival was measured from the date of
entry until death or December 1, 2009. Patients completed self-assessments with the Functional Assessment of Cancer Therapy
and Memorial Symptom Assessment Scale-Short Form. Analysis of variance was used to test differences between groups in
continuous variables; a generalized Wilcoxon test was used for differences between groups for survival.
Results. The average age in the Validation Cohort was 66.5 years and 98% were men. The majority of patients had
metastatic cancer (90%), with lung (28%) and prostate (26%) cancers being predominant. The median Karnofsky
Performance Status was 70. Median survival was 33, 46.5, 124, and 209.5 days for the four prognostic groups (P < 0.0001, all
pair-wise comparisons P < 0.02).
Conclusion. The four prognostic groups remained distinct in the prospective cohort. Small differences in patient-reported
physical well-being can halve survival estimates. Patient-reported outcomes can correct for physician overestimate of
prognosis. This study provides a way to use patient-reported outcomes for prognosis in patients with advanced cancer, with
important implications for assessment. J Pain SymptomManage 2015;50:313e320. Published by Elsevier Inc. on behalf of American
Academy of Hospice and Palliative Medicine.
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Despite the wealth of biomedical information, an
accurate prognostic estimation by clinicians for pa-
tients with advanced cancer remains challenging.1An abstract of this work was presented at the 2010 Sci-
entific Meeting of the American Society of Clinical
Oncology, Chicago IL (J Clin Oncol 2010; 28(Suppl). ab-
stract 9040).
Published by Elsevier Inc. on behalf of American Academy of Hospice
and Palliative Medicine.Prognostic scoring systems are currently based on
clinician estimates, sometimes combined with labora-
tory or radiographic findings, or listing of symptoms.2
Well-known examples include the Palliative Perfor-
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validated in additional populations.6,7 However, these
rely on clinician estimates, which consistently overesti-
mate survival.8e10 The reason for clinician overestima-
tion is unknown. Accurate physician estimates of
prognosis can increase hospice stay by 20 days.11
The finding that patient-rated outcomes are predic-
tive of survival in cancer patients12 has led to interest
in whether patient-rated outcomes can help with
developing better prognostic estimates. Such an
approach could further patient-centered care and be
incorporated into clinical encounters and help in
resource-constrained settings.
We previously reported a recursive partitioning algo-
rithm (RPA) that incorporates only patient-reported
outcomes to define prognostic groups. An RPA is a
method of building decision trees to model out-
comes.13 The entire patient group is divided into
two subgroups as identified by a characteristic, such
as the Karnofsky Performance Status (KPS), that iden-
tifies the subgroups that are most different in the
outcome (survival). These two subgroups are again
partitioned on the basis of another characteristic,
thus creating a tree structure. The process is
continued until no further subdivisions are worth-
while for prognostic purposes. The RPA derivation
process identifies cut points in factors and allows for
inspection of interactions between prognostic factors.
We were interested in this approach as RPA prognostic
groups are easily used for patients in a clinic setting.
The RPA decision tree was derived from an analysis
of pooled data from prospective studies of veterans
with advanced cancer from October 1994 to October
2000 and is based on KPS, the Functional Assessment
of Cancer Therapy (FACT) quality of life (QOL) sub-
scale for physical well-being (PWB), and the MemorialFig. 1. Flow diagram for analysis data sets. (Validation) CohSymptom Assessment Scale-Short Form (MSAS-SF)
subscale for physical symptom distress (PHYS). The
RPA decision tree resulted in four distinct groups
with statistically different median survivals.14
We present the results of a prospective confirmatory
study of the RPA prognostic groups in veterans with
cancer.Methods
A prospective validation cohort (VC) study
comprised patients from three prospective studies of
veterans with advanced cancer: one in cancer pain15
and the other two in palliative care.16,17 All patients
were followed for survival. These patients were both
inpatients and outpatients from Institutional Review
Board-approved studies at the Veterans Affairs (VA)
New Jersey Health Care System who enrolled between
August 1999 to September 2009. Survival was
measured from the date of entry until death or end
of follow-up on December 1, 2009. Dates of death
were confirmed with the Social Security Death Index
and/or VA records. Eligibility for the pain study was
determined by the presence of severe pain related to
cancer. Eligibility for the palliative care studies was pa-
tient and physician determination that palliative goals
of care were appropriate. We checked for patients who
might have been enrolled on more than one study to
remove any redundancies. For comparison purposes,
the First Cohort (FC) was the same as previously
described6 but patients with no active cancer were
removed.
Patients were evaluated for KPS18 and with patient-
rated instruments, including the FACT19 and MSAS-
SF.20 The responses of patients at the time of study entryort 2; (First) Cohort 1; NED ¼ no evidence of disease.
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Measures
The FACT is a validated 28-item general patient-
rated measure of QOL for cancer patients with any tu-
mor type. Each item is scored from 0 to 4 and
anchored from ‘‘not at all’’ to ‘‘very much.’’ The
PWB subscale, which forms part of the RPA algorithm,
includes seven items: lack of energy, nausea, illness
causing trouble in meeting the needs of the family,
pain, side effects of treatment, feeling ill, and being
forced to spend time in bed. The PWB subscale takes
one to two minutes to be completed by a patient or
with the help of a nurse.Table
DemographicsdSubje
Demographic Variable First Cohort
Age
N 417
Mean 66.1
SD 11.1
Min 27
Max 96
Gender
Male 409 (98.08%)
Female 8 (1.92%)
KPS
100 21 (5.04%)
90 38 (9.11%)
80 161 (38.61%)
70 23 (5.52%)
60 78 (18.71%)
50 35 (8.39%)
40 44 (10.55%)
30 11 (2.64%)
20 6 (1.44%)
Extent of disease
Local 10 (2.40%)
Loco-regional 36 (8.63%)
Regional-advanced 27 (6.47%)
Metastatic 344 (82.49%)
Cancer
Head and neck 26 (6.24%)
Lung 118 (28.30%)
Mesothelioma 0
Breast 1 (0.24%)
Esophageal 8 (1.92%)
Prostate 126 (30.22%)
Bladder 10 (2.40%)
Colorectal 40 (9.59%)
Stomach 3 (0.72%)
Pancreatic 8 (1.92%)
Ovarian 17 (4.08%)
Hepatic 2 (0.48%)
Renal 5 (1.20%)
Melanoma 2 (0.48%)
Sarcoma 5 (1.20%)
Hodgkin’s 3 (0.72%)
Non-Hodgkin’s 16 (3.84%)
Leukemia 9 (2.16%)
Multiple myeloma 12 (2.88%)
Myeloid leukemia 1 (0.24%)
Myelodysplasia 1 (0.24%)
Unknown 4 (0.96%)
KPS ¼ Karnofsky Performance Status.The MSAS-SF is a validated patient-rated instrument
that includes patient assessment for symptom fre-
quency or distress for 32 highly prevalent physical
and psychological symptoms. Each symptom is scored
from 0 to 4 ranging from ‘‘no symptom’’ to ‘‘very
much.’’ The PHYS subscale includes 12 prevalent
symptoms: lack of energy, pain, lack of appetite,
feeling drowsy, constipation, dry mouth, nausea, vom-
iting, change in taste, weight loss, feeling bloated, and
dizziness. The MSAS-SF can take one to five minutes to
be completed by a patient or with the help of a nurse.
Statistical Analysis
At the time of analysis, 99% of the patients had
died. Analysis of variance modeling was used to test1
ct Characteristics
Validation Cohort Total
463 880
66.8 66.5
11.1 11.1
35 27
94 96
456 (98.49%) 865 (98.30%)
7 (1.51%) 15 (1.70%)
4 (0.86%) 25 (2.84%)
27 (5.83%) 65 (7.39%)
107 (23.11%) 268 (30.45%)
96 (20.73%) 119 (13.52%)
94 (20.30%) 172 (19.55%)
68 (14.69%) 103 (11.70%)
56 (12.10%) 100 (11.36%)
8 (1.73%) 19 (2.16%)
3 (0.65%) 9 (1.02%)
1 (0.22%) 11 (1.25%)
3 (0.65%) 39 (4.43%)
13 (2.81%) 40 (4.55%)
446 (96.33%) 790 (89.77%)
38 (8.21%) 64 (7.27%)
130 (28.08%) 248 (28.18%)
4 (0.86%) 4 (0.45%)
6 (1.30%) 7 (0.80%)
10 (2.16%) 18 (2.05%)
105 (22.68%) 231 (26.25%)
11 (2.38%) 21 (2.39%)
46 (9.94%) 86 (9.77%)
10 (2.16%) 13 (1.48%)
19 (4.10%) 27 (3.07%)
0 17 (1.93%)
16 (3.46%) 18 (2.05%)
10 (2.16%) 15 (1.70%)
6 (1.30%) 8 (0.91%)
3 (0.65%) 8 (0.91%)
0 3 (0.34%)
14 (3.02%) 30 (3.41%)
17 (3.67%) 26 (2.95%)
13 (2.81%) 25 (2.84%)
0 1 (0.11%)
0 1 (0.11%)
5 (1.08%) 9 (1.02%)
Table 2
MSAS-Short Form Subscale Scores
MSAS-SF Subscale First Cohort Validation Cohort Total
GDI
N 417 463 880
Mean (SD) 1.15 (0.83) 1.43 (0.78) 1.30 (0.82)
Range 0e3.24 0e3.6 0e3.6
P-value <0.0001
PSYCH
N 417 463 880
Mean (SD) 0.88 (0.87) 1.09 (0.91) 0.99 (0.90)
Range 0e3.73 0e4.00 0e4.00
P-value 0.0005
PHYS
N 417 463 880
Mean (SD) 0.98 (0.87) 1.28 (0.91) 1.14 (0.77)
Range 0e3.13 0e4.00 0e4.00
P-value <0.0001
TMSAS
N 415 463 878
Mean (SD) 0.75 (0.53) 0.99 (0.52) 0.87 (0.54)
Range 0e2.51 0e2.72 0e2.72
P-value <0.0001
NS
N 413 463 876
Mean (SD) 10.29 (5.76) 12.91 (5.66) 11.67 (5.85)
Range 0e30 0e30 0e32
P-value <0.0001
MSAS ¼ Memorial Symptom Assessment Scale; GDI ¼ Global Distress Index;
PSYCH ¼ Psychological Subscale; PHYS ¼ Physical Subscale; TMSAS ¼ Total
Memorial Symptom Assessment Subscale (Short Form); NS ¼ Number of
Symptoms.
Table 3
FACT-G Subscale Scores
FACT-G Subscale First Cohort Validation Cohort Total
PWB
N 416 458 874
Mean (SD) 20.14 (6.01) 19.02 (5.83) 19.55 (5.94)
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variables; the generalized Wilcoxon test was used for
differences between groups for survival. These
methods have been used to validate other RPA
algorithms.21,22
Concordance probability23 was determined to
evaluate fit of the RPA groups to the data. Concor-
dance can range from 0 to 1, with a higher value indi-
cating better fit, and 1 indicating perfect fit. A Cox
regression analysis was performed to compare
survival between the different RPA groups by cohort.Range 0e28 2e28 0e28
P-value 0.0051
SFWB
N 416 459 875
Mean (SD) 19.92 (5.75) 19.44 (6.51) 19.67 (6.16)
Range 3e28 0e28 0e28
P-value 0.2490
EWB
N 415 458 873
Mean (SD) 16.13 (4.09) 18.54 (4.80) 17.39 (4.63)
Range 0e20 0e24 0e24
P-value <0.0001
FWB
N 415 458 873
Mean (SD) 14.90 (7.13) 11.27 (6.70) 12.99 (7.14)
Range 0e28 0e28 0e28
P-value <0.0001
SUMQOL
N 415 458 873
Mean (SD) 71.07 (16.69) 68.31 (17.08) 69.63 (16.94)
Range 22.6e104 21e108 21e108
P-value 0.0162
PWB ¼ Physical Well-Being Subscale; SFWB ¼ Social Family Well-Being
Subscale; EWB ¼ Emotional Well-Being Subscale; FWB ¼ Functional Well-
Being Subscale; SUMQOL ¼ Sum of Quality of Life Subscale.Results
A total of 953 patients were available in the two co-
horts; 479 in the FC and 474 in the VC. Figure 1
presents the patient flow for analysis. There were
62 patients who were excluded from the FC with the
primary reason being the patients had no disease
(8.8%). In the VC, only 11 patients were excluded
(2.3%).
Demographic features for all analyzed patients are
summarized in Table 1. Race is not reported because
it was not collected in the FC. Data summarizing and
comparing the FC and the VC are presented in
Tables 1e3. In Table 1, VC patients were more likely
to have metastatic disease (P < 0.0001) and a lower
performance status (P < 0.0001); the site of cancer
was similar across cohorts and were primarily lungand prostate cancers. VC patients had higher scores
in the MSAS-SF PHYS (Table 2) (P < 0.0001), indi-
cating more symptoms. QOL, as measured by the
FACT PWB, was worse in VC patients (P ¼ 0.0051)
(Table 2) compared with FC patients. There were
more RPA Group 3 patients in the VC and more
RPA Group 4 patients in the FC (P < 0.0001)
(Table 3). Median survival was 175 days (95% CI
153, 237) in FC patients compared with 111 days
(95% CI 95, 129) in VC patients (P < 0.0001). Missing
data were minimal, with incompletely filled forms for
two of the patients.
Median survival for the FC by RPA groups was 25
days (95% CI 18, 34) for Group 1, 76 days (95% CI
45, 137) for Group 2, 166 days (95% CI, 141, 216)
for Group 3, and 668 days (95% CI 512, 981) for
Group 4. Median survival for the VC by RPA groups
was 33 days (95% CI 20, 46) for Group 1, 46 days
(95% CI 35, 76) for Group 2, 124 days (95% CI 101,
150) for Group 3, and 209 days (95% CI 156, 251)
for Group 4 (Table 4, Fig. 2). Differences in survival
were statistically significant in pair-wise comparisons
(P < 0.02) of the groups in the VC. The concordance
probability is 0.6981 (SD 0.0112) for the FC and
0.5927 (SD 0.0122) for the VC.
For the Cox regression analyses, in the FC, there was
discrimination between each group compared with
RPA Group 4 (the best group); in the VC, discrimina-
tion was significant for Groups 1 and 2, and borderline
for Group 3 (Table 5).
Table 4
Median Survival by RPA Groups in Validation Cohort
Group KPS FACT PWB
MSAS
SF PHYS
First Cohort
Number of
patients (416)a
Validation Cohort
Number of
patients (463)
First Cohort Median
Survival (d)
(95% CI)
Validation Cohort
Median Survival (d)
(95% CI)
1 <50% 61 67 25 (18e34) 33 (20e46)
2 $50% <25 30 58 76 (45e137) 46 (35e76)
3 $50% $25 >0.6 170 248 166 (141e216) 124 (101e150)
4 $50% $25 #0.6 155 90 668 (512e981) 209 (156e383)
RPA ¼ recursive partitioning analysis; KPS ¼ Karnofsky performance status; FACT PWB ¼ Functional Assessment of Cancer Therapy Physical Well-Being Subscale;
MSAS SF PHYS ¼ Memorial Symptom Assessment Scale-Short Form Physical Subscale.
For 1 vs. 2, P < 0.0136; 2 vs. 3, P < 0.0001; 3 vs. 4, P < 0.0009.
aOne patient in the First cohort was missing a value for the physical well-being subscale and was not assigned an RPA group.
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We prospectively validated an RPA algorithm based
on KPS and patient-rated outcomes on a second
cohort of patients with advanced cancer. The four
RPA prognostic groups showed distinct survivals in
the VC of patients (Table 4, Fig. 2).
This algorithm is relevant to prognostic assessment
in patients with advanced cancer who have received
treatment(s) and are considering their options.
Currently, the timeliness of physician discussion of
poor prognosis with patients has become an area of
concern.24e26 We think that physicians rely on a low
KPS before deciding it is time to discuss hospice. Wait-
ing for a poor performance status (e.g., KPS < 50%)
to predict shortened survival is too late as poor perfor-
mance status in patients with advanced cancer confers
a median survival of approximately two months,27 as
also seen in our data. This leads to delayed hospice
referral as patients and families try to absorb and
cope with this information before accepting referral.
Conversely, for patients with advanced cancer in
the KPS >50% range, prognosis is difficult as
individual patients may live either longer or shorter
than predicted.28 What is needed is a way to distin-
guish a patient with ‘‘good’’ KPS who will likely0.
00
0.
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0.
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0.
75
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00
90 69 47 29 22 16RPAGroup = 4
248 140 79 55 42 29RPAGroup = 3
58 20 11 6 4 2RPAGroup = 2
67 15 8 5 3 2RPAGroup = 1
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RPAGroup = 3 RPAGroup = 4
Fig. 2. Kaplan-Meier survival by RPA prognostic group for
validation cohort. RPA ¼ recursive partitioning algorithm.live longer from a patient with ‘‘good’’ KPS who
will not.
Patient-rated outcomes may be a way to stratify pa-
tients with the same KPS as QOL and symptoms start
to deteriorate before the KPS in patients with
advanced cancer.16,29,30 While patient-reported out-
comes are a relatively simple and inexpensive source
of prognostic information, clinical application to prac-
tice has been limited, perhaps because of the percep-
tion that QOL and symptom assessments are
time-consuming, that items on the scales are difficult
to remember, and that laboratory and radiographic
findings are more important.
The algorithm provides a partial explanation for
why physicians overestimate prognosis. The FACT
PWB subscale score is able to demarcate two distinct
survival groups in patients with KPS >50%. The
remarkable finding is that the first cut point is a
FACT PWB subscale score of 25, which is close to
the ideal score of 28. This model predicts that even re-
sponses of ‘‘a little bit’’ to three items of the FACT
PWB subscale will place the patient in a much shorter
survival range, decreasing median survival by more
than 50% (Table 4). ‘‘Looking well’’ is not enough.
Emphasizing performance status assessments can
miss small drops in physical well-being. Unlike other
algorithms, patients with a longer expected survival
also can be identified with the additional use of the
MSAS-SF PHYS subscale for the second cut point.
These considerations support the relevance of longitu-
dinal patient-reported measurements in clinical
practice.31
The items in the PWB subscale are ones commonly
used by clinicians in usual conversation. A lower PWB
score may be useful in overcoming physician reluc-
tance to discuss end-of-life issues in the absence of
symptoms32 as these discussions can be helpful to pa-
tients and their families.33 Patients with lower physical
well-being also should undergo careful symptom
assessment. Applying this algorithm provides a
focused QOL and symptom assessment that can help
individualize care.34
Table 5
Cox Regression Analysis of RPA Groups by Cohort
RPA Group
First Cohort Validation Cohort
HR vs. RPA 4 P-value HR vs. RPA 4 P-value
1 20.3 <0.0001 3.1 <0.0001
2 4.7 <0.0001 2.3 <0.0001
3 2.2 <0.0001 1.2 0.0996
RPA ¼ recursive partitioning analysis; HR ¼ hazard ratio.
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RPA-derived decision trees, symptom and QOL
subscales, and a combination of observer- and
patient-reported outcomes. RPA decision trees have
been successfully developed and applied in other palli-
ative settings, such as survival of patients with brain
metastases22 and radiation oncology patients,35 and
in medical oncology.36,37
This algorithm is the first validated RPA algorithm
to use patient-reported outcomes to determine prog-
nosis and uses patient-rated severity of QOL
subscales (FACT PWB) and symptom subscales
(MSAS-SF PHYS) rather than individual symptoms.
Generally, the prognostic components of patient-
reported outcomes have centered on physical well-
being in QOL assessments38 and various symptoms.39
One large-scale meta-analysis confirmed the signifi-
cance of QOL and fatigue as predictors of survival.40
However, another recent large meta-analysis was un-
able to show that individual symptoms can supplant
performance status as predictors.41 This algorithm
suggests that groups of symptoms may be more infor-
mative than individual symptoms. The FACT PWB
subscale42 and the MSAS-SF PHYS subscale43 have
been independent predictors of survival in other
studies. Others have found that a combination of
physician- and patient-reported outcomes may
improve prognostic predictions44 and clinical trial
adverse event reporting.45
Features of the VC include shorter survival, espe-
cially for Group 4, and this is most likely the result
of delay in initiating palliative care as more treatment
options became available for patients with metastatic
solid tumors. The VC also was more ill than the first
group, with a lower performance status and worse
QOL and symptom scores. The difference in concor-
dance probability of the FC and VC most likely reflects
differences in the patient population. Analysis of sur-
vival by Cox regression (Table 5) indicates that the
RPA groups are distinct, although the difference be-
tween RPA Group 3 and Group 4 was not striking in
the VC patients. These data support the construct val-
idity and calibration of the model and illustrate how
the model may be sensitive to changes in the popula-
tion being studied.It is unknown whether modifying patient-rated data,
such as through better symptom control, will affect
survival, and the prognostic value of this classification
scheme. This will have to be tested in future studies.
Strengths of the study are the large number of pa-
tients and wide variety of diagnoses collected in a pri-
mary hematology oncology setting. The data on the
FACT and MSAS SF are the largest data set to be re-
ported to date from the VA system. The VA health
care system is the largest provider of integrated cancer
care in the U.S., treating approximately 3% of newly
diagnosed patients with cancer nationwide.46 One
weakness is the small percentage of female patients,
which is to be expected in a VA hospital, and the sec-
ond is the small proportion of patients with hemato-
logic malignancies. A third weakness in studies of
this kind is the difficulty of defining the inception
cohort. The patients in the VC had advanced cancer
where the goal of care was either pain control and/
or a palliative focus.
Further work is needed in other populations, other
malignancies, and with shorter symptom assessment
instruments.47 Ongoing analyses will lead to the devel-
opment of new RPA algorithms for future study and
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